VAC Regimen for AML Patients Who Failed to Response to VA Regimen
Status:
RECRUITING
Trial end date:
2026-12-01
Target enrollment:
Participant gender:
Summary
Chidamide in combination with venetoclax and azacitidine (VAC) were expected to improve remission rate of patients following to VA regimen treatment failure.
Phase:
PHASE2
Details
Lead Sponsor:
The First Affiliated Hospital of Soochow University
Collaborators:
Affiliated Hospital of Nantong University Jining Medical University Northern Jiangsu People's Hospital The First Affiliated Hospital of Bengbu Medical University The Second People's Hospital of Huai'an